単細胞RNA配列解析は,肝細胞がんの進行の主要な原動力としてTOP2Aを明らかにした.
PubMedで要約を見る
まとめ
この要約は機械生成です。トポイソメラーゼIIα (TOP2A) は肝細胞癌 (HCC) で上位調節され,腫瘍の進行を促します. TOP2Aのノックダウンは,HCC細胞の増殖,移動,侵入を阻害し,HCC治療の潜在的な治療目標を提供します.
科学分野
- 腫瘍学
- 分子生物学
- バイオ情報学
背景
- 肝細胞癌 (HCC) は,有効な治療戦略が限られている世界的な健康問題です.
- HCCの進行を促す分子メカニズムを理解することは,新しい治療法の開発に不可欠です.
研究 の 目的
- HCCにおけるトポイソメラーゼIIα (TOP2A) の生物学的機能と腫瘍学的作用を調査する.
- HCCの潜在的な診断バイオマーカーと治療標的としてTOP2Aを調査する.
主な方法
- HCC組織のバイオインフォマティクス分析と単細胞RNAシーケンシング (scRNA-seq)
- 定量PCR (QPCR) とWestern Blottingにより,TOP2A発現とsiRNAのノックダウン効率を検証する.
- CCK8,創傷治癒,トランスウェル,フローサイトメトリーを含むインビトロ機能検査で,増殖,移動,侵入,アポトーシスを評価する.
主要な成果
- TOP2AはHCC組織で著しく上昇し,予後不良と相関していました.
- siRNA媒介によるTOP2Aノックダウン (> 70%の効率) は,HCC細胞の増殖,侵入,移動を有意に抑制し,同時にアポトーシスを促進した.
- scRNA- seqデータによると,TOP2AはSPP1- CD44軸経由でTmem- to- Texの分化を促進し,免疫逃避に潜在的に貢献している.
結論
- TOP2Aは,HCCにおける重要な腫瘍発生因子であり,独立した予後生物マーカーである.
- TOP2Aをターゲットにすることで,HCCの進行を抑制し,免疫回避を克服することができます.
- TOP2Aは,HCCの免疫療法における有望な治療目標です.
関連する概念動画
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

